<DOC>
	<DOC>NCT01661153</DOC>
	<brief_summary>This prospective observational study will evaluate the use in clinical practice, efficacy and safety of Avastin (bevacizumab) in combination with paclitaxel in first line in patients with HER2-negative metastatic breast cancer. Data will be collected from eligible patients for up to 2.5 years.</brief_summary>
	<brief_title>An Observational Study of Avastin (Bevacizumab) in Combination With Paclitaxel in First-Line Treatment in Patients With HER2-Negative Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Adult patients, &gt;/= 18 years of age Locally recurrent or metastatic breast cancer No prior treatment for metastatic or locally recurrent disease Eastern Cooperative Oncology Group (ECOG) performance status 02 History or clinical evidence of brain metastases Pregnancy Uncontrolled hypertension ( systolic &gt; 150 mmHg and/or diastolic &gt; 100 mmHg) or clinically significant (i.e. active) cardiovascular disease Major surgical procedure or significant traumatic injury within 28 days prior to enrolment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>